Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kaken, Axcelead Hook Up on New Drug Discovery
January 12, 2023
- Mitsubishi Tanabe to End Sales of Lexapro as Deal Expires
January 12, 2023
- Takatsugu Den Tapped as Biogen Japan’s New President
January 12, 2023
- Opdivo Extends Best-Selling Streak to 12 Months: Encise
January 12, 2023
- Eisai Files Alzheimer’s Med Lecanemab in Europe
January 12, 2023
- Kaken Snags Japan Rights to CymaBay Med for Primary Biliary Cholangitis
January 11, 2023
- Otsuka, Schrodinger in Neurology Drug Discovery Collaboration
January 11, 2023
- US FDA Accepts Rexulti sNDA for Alzheimer’s Agitation: Otsuka/Lundbeck
January 11, 2023
- Astellas to Test Selecta’s IgG Protease with Pompe Gene Therapy
January 11, 2023
- NeuroDerm’s Parkinson’s Med Hits Main Goal in PIII
January 11, 2023
- AnGes, miRaX Ink Option Pact for MicroRNA Research
January 11, 2023
- Forxiga Now Available for Heart Failure Regardless of LVEF
January 11, 2023
- AbbVie, Eisai to End Humira Copromotion in June
January 11, 2023
- Japan Ethical Drug Sales Up 2.1% in November: Crecon
January 11, 2023
- Official Margin Proposal Only Realistic for Partial Introduction: Crecon President
January 10, 2023
- Top-Tier Pharma Companies, Mid-Sized Peers Mixed on Special PMP Step: New Year Confab
January 10, 2023
- Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
January 10, 2023
- Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
January 10, 2023
- Takeda’s TAK-755 Shows Promising PIII Interim Data for Ultra-Rare Blood Clotting Disorder
January 10, 2023
- Kaken Earns Japan Rights to CAH Med, Poised to Boost Rare Disease Biz
January 10, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…